SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil (BATL) is surging as escalating geopolitical tensions and reports of the Strait of Hormuz's closure significantly impact oil prices. Community discussion is rife with short squeeze speculation given the low float and high cost to borrow, though many also voice concerns about a speculative pump and dump.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is a major talking point after its recent earnings call provided optimistic long-term revenue projections, including multibillion-dollar potential, and affirmed it is fully funded for deploying its satellite constellation. The community is highly anticipating additional announcements this week, alongside enthusiasm for newly disclosed strategic partnerships aiming to expand direct-to-device connectivity globally.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending after its Q3 earnings report, which, despite beating estimates, triggered a sharp after-hours sell-off due to market interpretation of conservative Q4 sales guidance. Community sentiment is split, with many highlighting strong fundamentals and massive AI infrastructure spending as reasons to buy the dip, while others remain cautious given previous volatility and concerns about valuation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology (GRRR) is trending as investors react to its full-year 2025 results, featuring record revenue and a significant profitability turnaround. While many highlight its robust cash position and expanding AI infrastructure pipeline, community debate focuses on its persistent low valuation amidst perceived short-seller pressure and historical price volatility.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending significantly lower after its Q4 earnings, with the community focused on weaker forward guidance, leadership departures, and the perceived slow monetization of AI, fueling intense debate on whether the sharp sell-off is an overreaction or a justified response to slowing growth in the SaaS sector.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending following the significant milestone of receiving 100% FAA Means of Compliance acceptance for its Midnight aircraft, which the community views as a major de-risking event toward its 2026 passenger flight target, despite ongoing discussions around financial performance and the competitive eVTOL landscape.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy is trending as escalating Middle East tensions, including Iran's threats to close the Strait of Hormuz and attacks on oil infrastructure, drive expectations for surging crude prices. The community is actively discussing its potential for a substantial rally, drawing parallels to past energy spikes, despite some frustration over its relative performance compared to sector peers and concerns about dilution.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending following its strategic acquisition of StereoLabs, which combines high-resolution digital lidar with AI vision and perception software to establish a unified Physical AI platform. This move, coupled with recent strong quarterly earnings showcasing impressive gross margins and a reinforcing path to profitability, has sparked bullish community discussion regarding the company's leadership in robotics, industrial automation, and autonomous systems.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as Nvidia's strategic investments in optical interconnects fuel community excitement that POET's unique wafer-scale photonics technology is poised for a significant revenue ramp with hyperscale AI data centers. Investors are actively discussing potential major partnerships and eagerly awaiting further commercialization updates, particularly ahead of the upcoming OFC Conference.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is trending as it recently achieved an all-time closing high and continues to attract significant investor inflows, with the community discussing its appeal as a steady, diversified long-term investment amidst a volatile and directionless market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li><li>As of Dec. 26, 72 deaths have occurred, the company said earlier, highlighting that it had previously expected 80 patient deaths to occur by December end.</li><li>Maxim analyst Jason McCarthy previously noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.</li></ul>Shares of Sellas Life Sciences (SLS) garnered the spotlight on Stocktwits on Friday as retail traders contemplated the company’s upcoming results from its late-stage trial for Galinpepimut-S (GPS). &nbsp;SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user expressed optimism for data from the trial spurring a rally. “Till then it’s the accumulation game,” he said.<stembedurl>https://www.stocktwits.com/Heypentaco/message/646154506</stembedurl>Another opined that the GPS will be worth over $180/share to big pharma companies looking to buy Sellas.<stembedurl>https://www.stocktwits.com/67X_ROI_Q1_2026/message/646149937</stembedurl>Another user opined that now is the time to buy more shares of the company.<stembedurl>https://www.stocktwits.com/Polsky/message/646158337</stembedurl>Overall, retail sentiment around SLS stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. According to Stocktwits data, retail chatter around the stock has increased by about 453% over the past 90 days.<h2 class="st-heading-2">The GPS Trial</h2>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of Dec. 26, 72 deaths have occurred, the company said earlier, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou then said.Maxim analyst Jason McCarthy then noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at further potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have more than quadrupled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-are-us-bank-stocks-seeing-heavy-selloffs-today/cZTcHyHRITv">Why Are US Banks Seeing Heavy Selloffs Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest?

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.

Equity

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.


<ul class="summary-bullets"><li>Sellas’ CEO referenced the company’s Phase 3 REGAL trial in a LinkedIn post, following its December update that the final analysis was approaching for GPS as a therapy in AML.</li><li>Anson Funds Management recently disclosed that it held a 4.9% stake in Sellas.</li><li>Last month, Sellas partnered with IMPACT-AML to advance AML treatments.</li></ul>Sellas Life Sciences Group Inc. (SLS) generated significant retail buzz on Monday as the stock shot up more than 15% to its highest levels in more than a month.According to Stocktwits data, message volume on the platform increased nearly 170% over the past 24 hours.<h2 class="st-heading-2">Retail Bullish On Potential Phase 3 REGAL Trial Results</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/SLS">SLS</a> on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/Sellas_jpg_9c62bbaf10.webp" alt="Sellas.jpg">On Sunday, Angelos M. Stergiou, President and CEO of Sellas, made a reference to the company’s Phase 3 REGAL trial in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7431478609229438976/">post</a> on LinkedIn. Last December, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> it was nearing the final analysis from its Phase 3 REGAL trial for Galinpepimut-S (GPS) as a potential maintenance therapy in Acute Myeloid Leukemia (AML).AML is a fast-growing blood and bone marrow cancer in which abnormal white blood cells crowd out healthy cells.One user said the REGAL data was the “ultimate catalyst.”<stembedurl>https://stocktwits.com/kay91667/message/645624253</stembedurl>Another user said that “REGAL Phase 3 remains event-driven and approaching its final trigger.”<stembedurl>https://stocktwits.com/G_Trade/message/645600596</stembedurl>According to an SEC filing last week, Anson Funds Management disclosed that it held a 4.9% stake in the company, prompting a user to call it a “very exciting time” for shareholders.<stembedurl>https://stocktwits.com/Az2fl2025/message/645612860</stembedurl><h2 class="st-heading-2">IMPACT-AML Partnership</h2>Last month, Sellas partnered with IMPACT-AML, a European initiative dedicated to advancing AML treatments, to conduct a multi-site European clinical study of SLS009, the company’s selective CDK9 inhibitor.The stock came under some selling pressure in January over dilution fears after the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-falls-for-fourth-straight-session/cmU2FjBR4dH">said</a> it received about $26.5 million from the exercise of common stock warrants.Year-to-date, SLS shares have gained around 3%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sw-ip-pkg-stocks-slump-today/cZRtU4BR4yp">Why Did SW, IP, PKG Stocks Slump Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15%

According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours.

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading activity on Monday. Stock traders acquired 42,324 call options on the company. This is an increase...

Notable Thursday Option Activity: SLS, MDGL, ZG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in SELLAS Life Sciences Group Inc (Symbol: SLS), where a total volume of 38,228...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.8% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 9.8% - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 14.9% in January

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant decline in short interest in January. As of January 15th, there was short interest totaling 42,044,430 shares, a...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 7.4% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 7.4% - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.2% Higher - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.2% - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Stocktwits

Stocktwits Polls

Traders are eagerly awaiting crucial Phase 3 trial results, believing the prolonged silence and patient survival data strongly indicate overwhelmingly positive efficacy.

The stock has breached and held above the crucial $5 mark, which traders believe will open the doors for a new wave of institutional buying and increased demand.

There is a strong conviction that short sellers are in a precarious position, facing significant losses due to high short interest and the stock's upward momentum.

Investors are predicting substantial future price appreciation, with some anticipating targets of $100+ and comparisons to historical biotech surges.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLS News

SLSSELLAS Life Sciences Group Inc